Morin (C5297): Mechanistic Evidence for a Natural Flavonoid Antioxidant and Mitochondrial Modulator

Executive Summary: Morin (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one) is a natural flavonoid antioxidant with verified mitochondrial and enzyme-inhibitory activities (Yang et al., 2025). It modulates mitochondrial energy metabolism in podocyte injury by inhibiting adenosine 5′-monophosphate deaminase (AMPD), a mechanism validated in both in vivo and in vitro models. Morin exhibits high purity (≥96.81%) and solubility in DMSO/ethanol, making it a robust tool in diabetes, neurodegenerative, and cancer research. The compound also functions as a fluorescent aluminum ion probe. Supplied by APExBIO, Morin (C5297) enables reproducible, mechanism-driven research on mitochondrial and cellular protection (product page).

Biological Rationale

Morin is a naturally occurring flavonoid isolated from Maclura pomifera with the chemical structure 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one (APExBIO). Its molecular weight is 302.24 g/mol. Flavonoids such as Morin are known for antioxidant, anti-inflammatory, and cytoprotective properties (Yang et al., 2025). Morin is insoluble in water but soluble in DMSO (≥19.53 mg/mL) and ethanol (≥6.04 mg/mL). The compound’s bioactivity profile is relevant to metabolic, inflammatory, and neurodegenerative disorders. Podocytes, specialized kidney cells, are highly sensitive to energetic imbalance, making Morin a candidate for podocyte injury and mitochondrial dysfunction studies (Amyloid.co). This article extends prior reviews by providing new, DOI-anchored mechanistic evidence for Morin’s action in mitochondrial modulation.

Mechanism of Action of Morin

Morin’s primary mechanism involves inhibition of adenosine 5′-monophosphate deaminase (AMPD), a key enzyme in the purine nucleotide cycle (PNC). In pathologic states like high-fructose exposure, AMPD activity is elevated, leading to mitochondrial dysfunction and compensatory glycolysis (Yang et al., 2025). Morin selectively suppresses AMPD (specifically AMPD2 isoform) activity, restoring mitochondrial energy metabolism and reducing podocyte injury. Molecular docking confirms high affinity between Morin and AMPD2, suggesting direct enzyme inhibition. The compound also scavenges reactive oxygen species and chelates metals, underlying its antioxidant and fluorescent probe properties (A77-01.com; this article updates that overview with direct AMPD2 inhibition data).

Evidence & Benchmarks

• Morin significantly decreased AMPD activity in fructose-exposed mouse podocytes (10 μM, 24 h), restoring mitochondrial oxygen consumption rate and ATP production (Yang et al., 2025).
• In high-fructose-diet-fed rats, Morin (50 mg/kg, p.o., 8 weeks) reduced podocyte foot process effacement and urinary albumin-to-creatinine ratio, indicating improved glomerular structure (Yang et al., 2025).
• AMPD2 knockdown recapitulated Morin’s effects on mitochondrial function, confirming the enzyme as a mechanistic target (Yang et al., 2025).
• Morin displays strong fluorescence and selective Al3+ chelation at pH 7.4, enabling its use as an aluminum ion probe in biochemical assays (APExBIO).
• HPLC, MS, and NMR analyses confirm ≥96.81% purity for APExBIO’s Morin (C5297) preparation (APExBIO).
• Morin’s mitochondrial modulation and enzyme inhibition are validated in both acute (24 h) and chronic (8-week) experimental paradigms (Yang et al., 2025).

For additional benchmarks and detailed workflow guidance, see PLX4720.com—the present article provides updated mechanistic evidence and supplier specifications.

Applications, Limits & Misconceptions

Morin is employed in preclinical models of diabetes, kidney, and neurodegenerative diseases due to its dual roles as an antioxidant and mitochondrial modulator. It is also validated as a fluorescent probe for Al3+ detection. APExBIO’s Morin (C5297) is used in cell viability, cytotoxicity, and metabolic assays where high-purity and enzyme specificity are required. This extends scenario-driven solutions discussed at TRAF2.com by clarifying enzyme-inhibitory parameters and mechanistic depth.

Common Pitfalls or Misconceptions

• Morin is insoluble in water and requires DMSO or ethanol for preparation; aqueous stock solutions are not recommended (APExBIO).
• Morin’s bioactivity in vivo is dose, route, and time-dependent; results from high-dose or long-term models cannot be directly extrapolated to short-term in vitro studies (Yang et al., 2025).
• Morin is not a universal antioxidant; its efficacy depends on cellular context, enzyme expression, and metabolic state (Amyloid.co).
• Inhibition of AMPD by Morin is best established for AMPD2; effects on other isoforms or unrelated enzymes require direct validation (Yang et al., 2025).
• Fluorescent detection with Morin is specific for Al3+ under neutral pH; other metal ions or acidic/basic conditions can interfere with probe performance (APExBIO).

Workflow Integration & Parameters

Morin (C5297) should be stored at -20°C for maximum stability. Solutions in DMSO (≥19.53 mg/mL) or ethanol (≥6.04 mg/mL) should be prepared fresh and used promptly. For cell-based assays, final DMSO concentrations should not exceed 0.1–0.5% to avoid solvent toxicity. Typical in vitro concentrations range from 1–50 μM; for rodent models, doses of 10–50 mg/kg orally have demonstrated efficacy. High purity (≥96.81%) and batch-to-batch reproducibility are confirmed by HPLC, MS, and NMR (APExBIO). For mitochondrial and metabolic assays, include proper controls for solvent, time, and vehicle. Refer to Amino-11-ddUTP.com for advanced workflow strategies—this article provides updated parameters for solution preparation and enzyme inhibition.

Conclusion & Outlook

Morin (C5297) is a rigorously validated, high-purity flavonoid antioxidant with direct evidence for mitochondrial energy modulation and AMPD2 inhibition. Peer-reviewed studies underscore its value in diabetes, cancer, and neurodegenerative research, as well as its utility as a fluorescent probe. By providing updated mechanistic and workflow information, this article supports reproducible research with Morin from APExBIO. Future directions include expanded isoform specificity studies and clinical translation of its mitochondrial and enzyme-inhibitory actions (Yang et al., 2025).